Perspective Therapeutics CATX Accrued Manufacturing Costs
Accrued Manufacturing Costs at other companies
Other financials
Where this comes from
Reported directly by Perspective Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The official record: Perspective Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Perspective Therapeutics's accrued manufacturing costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Perspective Therapeutics's accrued manufacturing costs?
- Perspective Therapeutics (CATX) reported accrued manufacturing costs of $3.88M in Q1 2026.
- How has Perspective Therapeutics's accrued manufacturing costs changed year-over-year?
- Perspective Therapeutics's accrued manufacturing costs increased by 33.1% year-over-year, from $2.91M to $3.88M.
- What is the long-term trend for Perspective Therapeutics's accrued manufacturing costs?
- Over 2 years (2023 to 2025), Perspective Therapeutics's accrued manufacturing costs has grown at a 44.5% compound annual growth rate (CAGR), from $3.59M to $7.49M.